Activated p38-MAPK and gemcitabine sensitivity in recurrent ovarian cancer

Anticancer Research

Volumn 28, Issue 5 B, 2008, Pages 2975-2980

  Klotz, Renate ^a   Zeimet, Alain Gustave ^a   Reimer, Daniel ^a   Müller Holzner, Elisabeth ^a   Chamson, Martina ^a   Marth, Christian ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Chemoresistance; Gemcitabine; Ovarian cancer; p38 MAPK

Indexed keywords

DOXORUBICIN; GEMCITABINE; MITOGEN ACTIVATED PROTEIN KINASE P38; TOPOTECAN; TREOSULFAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MONOTHERAPY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TREATMENT RESPONSE;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; ENZYME ACTIVATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RETROSPECTIVE STUDIES;

EID: 55749102718     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Berkenblit A and Cannistra SA: Advances in the management of epithelial ovarian cancer. J Reprod Med 50(6): 426-438, 2005.
2. Kurzeder C, Sauer G and Deissler H: Molecular targets of ovarian carcinomas with acquired resistance to platinum/taxane chemotherapy. Curr Cancer Drug Target 6(3): 207-227, 2006.
3. Markman M, Webster K, Zanotti K, Peterson G, Kulp B and Belinson J: Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials. Gynecol Oncol 93: 699-701, 2004.
4. Bookman MA: Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic. Int J Gynecol Cancer 15(Suppl 1): 12-17, 2005.
5. Petru E, Angleitner-Boubenizek L, Reinthaller A, Deibl M, Zeimet AG, Vollger B, Stempfl A and Marth C: Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: A phase II Austrian AGO study. Gynecol Oncol 102(2): 226-229, 2006.
6. Bergman AM, Pinedo HM and Peters GJ: Determinants of resistance to 2'-2'-difluorodeoxycytidine (gemcitabine). Drug Resist Update 5: 19-33, 2002.
7. Habiro A, Tanno S, Koizumi K, Izawa T, Nakano Y, Osanai M, Mizukami Y, Okumura T and Kohgo Y: Involvement of p38 mitogen-activated protein kinase in gemcitabine-induced apoptosis in human pancreatic cancer cells. Biochem Bioph Res Commun 316: 71-77, 2004.
8. Nelson JM and Fry DW: Akt, MAPK (ERK1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition. J Biol Chem 276: 14842-14847, 2001.
9. Wada T and Penninger JM: Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23: 2838-2849, 2004.
10. Johnson GL and Lapadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298: 1911-1912, 2002.
11. Chang L and Karin M: Mammalian MAP kinase signalling cascades. Nature 410(6824): 37-40, 2001.
12. Zarubin T and Han J: Activation and signaling of the p38 MAP kinase pathway. Cell Res 15(1): 11-18, 2005.
13. Obata T, Brown GE and Yaffe M: MAP kinase pathways activated by stress: The p38 MAPK pathway. Crit Care Med 28(Suppl 4): N67-77, 2000.
14. Cuenda A and Rousseau S: p38 MAP-Kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 1773: 1358-1375, 2007.
15. Engelberg D: Stress-activated protein kinases-tumor suppressors or tumor initiators? Semin Cancer Biol 14(4): 271-282, 2004.
16. Han J and Sun P: The pathways to tumor suppression via route p38. Trends Biochem Sci 32(8): 364-371, 2007.
17. Chiacchiera F and Simone C: Signal-dependent regulation of gene expression as a target for cancer treatment: Inhibiting p38a in colorectal tumors. Cancer Lett 265: 16-26, 2008.
18. Xia Z, Dickens M, Raingeaud J, Davis RJ and Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270(5240): 1326-1331, 1995.
19. Junttila MR, Li SP and Westermarck J: Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J 22(4): 954-965, 2008.
20. Rustin GJ, Nelstrop AE, Bentzen SM, Piccart MJ and Bertelsen K: Use of tumour markers in monitoring the course of ovarian cancer. Ann Oncol 10(Suppl 1): 21-27, 1999.
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New Guidelines to Evaluate the Response to Treatment in Solid Tumors. J Natl Cancer Inst 92: 205-216, 2000.
22. Sehouli J: Review of gemcitabine-based combinations for platinum-resistant ovarian cancer. Int J Gynecol Cancer 15(Suppl 1): 23-30, 2005.
23. Garrington TP and Johnson GL: Organization and regulation of mitogen-activated protein kinase signalling pathways. Curr Opin Cell Biol 11: 211-218, 1999.
24. Loesch M and Chen G: The p38 MAPK stress pathway as a tumor suppressor or more? Front Biosci 13: 3581-3593, 2008.
25. Wong AST, Kim SO, Leung PCK, Auersperg N and Pelech SL: Profiling of protein kinases in the neoplastic transformation of human ovarian surface epithelium. Gynecol Oncol 82: 305-311, 2001.
26. Liang B, Wang S, Zhu XG, Yu YX, Cui ZR and Yu YZ: Increased expression of mitogen-activated protein kinase and its upstream regulating signal in human gastric cancer. World J Gastroenterol 11(5): 623-628, 2005.
27. Benhar M, Dalyot I, Engelberg D and Levitzki A: Enhanced ROS production in oncogenically transformed cells potentiates C-Jun N-terminal kinase and p38 mitogen-activated protein kinase. Mol Cell Biol 21(20): 6913-6926, 2001.
28. Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y, Siddik ZH, Mills GB and Claret FX: Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 278: 19245-19256, 2003.
29. Iyoda K, Sasaki Y, Horimoto M, Toyama T, Yakushijin T, Sakakibara M, Takehara T, Fujimoto J, Hori M, Wands JR and Hayashi N: Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma. Cancer 97: 3017-3026, 2003.
30. Branche D, Tanaka N, Jaeschke A, Ventura JJ, Kelkar N, Tanaka Y, Kyuuma M, Takeshita T, Flavell RA and Davis RJ: Mechanism of p38 MAP kinase activation in vivo. Genes Dev 17: 1969-1978, 2003.
31. Bulavin DV, Demidov ON, Saito S, Kauraniemi P, Phillips C, Amundson SA, Ambrosino C, Sauter G, Nebreda AR, Anderson CW, Kallioniemi A, Fornace AJ Jr and Appella E: Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 31(2): 210-215, 2002
32. Ventura JJ, Tenbaum S, Perdiguero E, Huth M, Guerra C, Barbacid M, Pasparakis M and Nebreda AR: p38alpha MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nat Genet 39(6): 750-758, 2007.
33. Hickson JA, Huo D, Vander Griend DJ, Lin A, Rinker-Schaeffer CW and Yamada SD: The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarina carcinoma. Cancer Res 66(4): 2264-2270, 2006.
34. Seidman R, Gitelman I, Sagi O, Horwitz SB and Wolfson M: The role of ERK 1/2 and p38 MAP-kinase pathways in taxol-induced apoptosis in human ovarian carcinoma cells. Exp Cell Research 265: 84-92, 2001.
35. Givant-Horwitz V, Davidson B, Lazarovici P, Schaefer E, Nesland JM, Tropé CG and Reich R: Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions. Gynecol Oncol 91: 160-172, 2003.
36. Harnett P, Buck M, Beale P, Goldrick A, Allan S, Fitzharris B, De Souza P, Links M, Kalim G, Davies T and Stuart-Harris R: Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand gynaecological oncology group study. Int J Gynecol Cancer 17(2): 359-366, 2007.